1 of 1
HOUSE DOCKET, NO. 1975 FILED ON: 1/19/2023
HOUSE . . . . . . . . . . . . . . . No. 1056
The Commonwealth of Massachusetts
_________________
PRESENTED BY:
Bradley H. Jones, Jr.
_________________
To the Honorable Senate and House of Representatives of the Commonwealth of Massachusetts in General
Court assembled:
The undersigned legislators and/or citizens respectfully petition for the adoption of the accompanying bill:
An Act establishing a commission to study maximum allowable costs lists.
_______________
PETITION OF:
NAME:DISTRICT/ADDRESS :DATE ADDED:Bradley H. Jones, Jr.20th Middlesex1/17/2023Kelly W. Pease4th Hampden1/25/2023Nicholas A. Boldyga3rd Hampden1/26/2023F. Jay Barrows1st Bristol1/26/2023Angelo L. D'Emilia8th Plymouth1/29/2023Hannah Kane11th Worcester1/30/2023Kimberly N. Ferguson1st Worcester2/1/2023 1 of 2
HOUSE DOCKET, NO. 1975 FILED ON: 1/19/2023
HOUSE . . . . . . . . . . . . . . . No. 1056
By Representative Jones of North Reading, a petition (accompanied by bill, House, No. 1056) of
Bradley H. Jones, Jr. and others for an investigation by a special commission (including
members of the General Court) relative to maximum allowable costs lists utilized by payers and
pharmaceutical benefit managers to identify the maximum amount health plans will pay for
certain prescription drugs. Financial Services.
[SIMILAR MATTER FILED IN PREVIOUS SESSION
SEE HOUSE, NO. 1121 OF 2021-2022.]
The Commonwealth of Massachusetts
_______________
In the One Hundred and Ninety-Third General Court
(2023-2024)
_______________
An Act establishing a commission to study maximum allowable costs lists.
Be it enacted by the Senate and House of Representatives in General Court assembled, and by the authority
of the same, as follows:
1 SECTION 1. Notwithstanding any general or special law to the contrary, there shall be a
2special commission established to investigate the use of maximum allowable costs lists, utilized
3by payers and pharmaceutical benefit managers to identify the maximum amount that a plan will
4pay for various prescription drugs. The commission’s review shall include, but not be limited to,
5current practices surrounding the determination and use of maximum allowable costs lists and
6their financial implications; industry-wide standardization for the development and use of
7maximum allowable costs lists; and transparency into the processes of developing and utilizing
8maximum allowable costs lists. 2 of 2
9 The commission shall consist of 10 members: the secretary of health and human services,
10or a designee; the speaker of the house of representatives, or a designee; the senate president, or
11a designee; the minority leader of the house of representatives, or a designee; the minority leader
12of the senate, or a designee; a representative from the Massachusetts Association of Health
13Plans; a representative from the Massachusetts Pharmacists Association; one person who shall be
14an advocate for health care providers, to be appointed by the governor; one person who shall be
15an advocate for pharmaceutical companies, to be appointed by the governor; and one person who
16shall be an advocate for pharmaceutical benefit managers, to be appointed by the governor.
17 The commission shall submit its report and findings, along with any draft of legislation,
18to the house and senate committees on ways and means, the joint committee on health care
19financing, and the clerks of the house of representatives and the senate within 180 days of the
20passage of this act.